Menarini has extended its commercial alliance for Teijin Pharma's gout drug febuxostat to a further 26 mainly emerging markets, acquiring exclusive distribution and marketing rights in Central and South America, the Commonwealth of Independent States and Australia/New Zealand.

In 2011, Bristol-Myers Squibb stopped a five-year slide in Japan, turning sales into the black for the first time since 2005.

Abbott Laboratories has extended its territorial rights to Kowa's hypolipaemic, pitavastatin, to Australia and New Zealand, where the US firm will exclusively market the product.